D‐dimer Levels Predict Ischemic Stroke in Infective Endocarditis
|
By LabMedica International staff writers Posted on 17 Feb 2020 |

Image: Blood test for D-dimer showed high sensitivity and specificity in the prediction of ischemic stroke in patients with infective endocarditis (Photo courtesy of Blue Horizon).
Infective endocarditis (IE) is a life‐threatening disease, especially in developing countries. IE may present many extra‐cardiac symptoms or signs, in which neurological complications are the most prominent and severe.
The manifestations of these neurological complications include ischemic stroke, hemorrhagic stroke, mycotic aneurysms, brain abscesses, meningitis, and encephalitis. Ischemic stroke, characterized by the interruption of cerebral blood flow, is a dominant and frequent neurological complication of left‐sided IE, as well as the main stroke type among all stroke cases in IE.
Infectious disease specialists at the Tianjin Medical University General Hospital (Tianjin, China) enrolled in a prospective study, a total of 173 consecutive patients with IE from January 2016 to December 2018. All patients were hospitalized for the first time with a definite diagnosis of IE based on the modified Duke criteria. The primary diagnosis of ischemic stroke was mainly based on clinical neurological symptoms and imaging manifestations on brain magnetic resonance imaging (MRI).
The team performed the measurement of plasma D‐dimer on admission using the VIDAS D‐dimer assay (bioMérieux, Marcy-l'Étoile, France), which has shown comparable sensitivity and specificity. The normal range of plasma D‐dimer is 0‐500 μg/L. Other hematological and biochemical data, such as white blood cell (WBC) count and C‐reactive protein (CRP), were also detected from peripheral blood samples collected on the next morning after admission. In addition, to identify causative organisms, at least three sets of blood cultures were obtained from all patients before the initiation of antibiotic therapy.
The scientists reported that ischemic stroke was observed in 38 (22%) patients during 6‐month follow‐up since definite diagnosis of IE. Patients with ischemic stroke had significantly higher levels of plasma D‐dimer than those of patients without stroke (4,982 versus 2,205 μg/L). Positive results of blood cultures were obtained from 107 (62%) patients. Streptococcus identified in 40 (23%) patients was the most common microorganism, accounting for 37% of all positive blood cultures. The secondary dominant causative agent was Staphylococcus aureus, isolated in 33 (19%) patients and 31% of all positive blood cultures.
In addition, Staphylococcus aureus infection (Hazard Ratio (HR): 1.96), mitral valve vegetation (HR: 1.52), and higher levels of on‐admission plasma D‐dimer (HR: 1.35) were significantly associated with ischemic stroke. Moreover, D‐dimer levels ≥3,393 μg/L served as a strong predictor for ischemic stroke in patients with IE, and the sensitivity and specificity were 78% and 83%, respectively.
The authors concluded that their study revealed that higher levels of on‐admission plasma D‐dimer showed high sensitivity and specificity in the prediction of ischemic stroke, which occurred mostly in the first three months after the diagnosis of IE. On the one hand, as a traditional and inexpensive biomarker, plasma D‐dimer may help clinicians identify high‐risk IE patients for ischemic stroke in a simple and quick way. The study was published on February 3, 2020 in the Journal of Clinical Laboratory Analysis.
Related Links:
Tianjin Medical University General Hospital
bioMérieux
The manifestations of these neurological complications include ischemic stroke, hemorrhagic stroke, mycotic aneurysms, brain abscesses, meningitis, and encephalitis. Ischemic stroke, characterized by the interruption of cerebral blood flow, is a dominant and frequent neurological complication of left‐sided IE, as well as the main stroke type among all stroke cases in IE.
Infectious disease specialists at the Tianjin Medical University General Hospital (Tianjin, China) enrolled in a prospective study, a total of 173 consecutive patients with IE from January 2016 to December 2018. All patients were hospitalized for the first time with a definite diagnosis of IE based on the modified Duke criteria. The primary diagnosis of ischemic stroke was mainly based on clinical neurological symptoms and imaging manifestations on brain magnetic resonance imaging (MRI).
The team performed the measurement of plasma D‐dimer on admission using the VIDAS D‐dimer assay (bioMérieux, Marcy-l'Étoile, France), which has shown comparable sensitivity and specificity. The normal range of plasma D‐dimer is 0‐500 μg/L. Other hematological and biochemical data, such as white blood cell (WBC) count and C‐reactive protein (CRP), were also detected from peripheral blood samples collected on the next morning after admission. In addition, to identify causative organisms, at least three sets of blood cultures were obtained from all patients before the initiation of antibiotic therapy.
The scientists reported that ischemic stroke was observed in 38 (22%) patients during 6‐month follow‐up since definite diagnosis of IE. Patients with ischemic stroke had significantly higher levels of plasma D‐dimer than those of patients without stroke (4,982 versus 2,205 μg/L). Positive results of blood cultures were obtained from 107 (62%) patients. Streptococcus identified in 40 (23%) patients was the most common microorganism, accounting for 37% of all positive blood cultures. The secondary dominant causative agent was Staphylococcus aureus, isolated in 33 (19%) patients and 31% of all positive blood cultures.
In addition, Staphylococcus aureus infection (Hazard Ratio (HR): 1.96), mitral valve vegetation (HR: 1.52), and higher levels of on‐admission plasma D‐dimer (HR: 1.35) were significantly associated with ischemic stroke. Moreover, D‐dimer levels ≥3,393 μg/L served as a strong predictor for ischemic stroke in patients with IE, and the sensitivity and specificity were 78% and 83%, respectively.
The authors concluded that their study revealed that higher levels of on‐admission plasma D‐dimer showed high sensitivity and specificity in the prediction of ischemic stroke, which occurred mostly in the first three months after the diagnosis of IE. On the one hand, as a traditional and inexpensive biomarker, plasma D‐dimer may help clinicians identify high‐risk IE patients for ischemic stroke in a simple and quick way. The study was published on February 3, 2020 in the Journal of Clinical Laboratory Analysis.
Related Links:
Tianjin Medical University General Hospital
bioMérieux
Latest Microbiology News
- Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
- AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
- New Test Measures How Effectively Antibiotics Kill Bacteria
- New Antimicrobial Stewardship Standards for TB Care to Optimize Diagnostics
- New UTI Diagnosis Method Delivers Antibiotic Resistance Results 24 Hours Earlier
- Breakthroughs in Microbial Analysis to Enhance Disease Prediction
- Blood-Based Diagnostic Method Could Identify Pediatric LRTIs
- Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
- Rapid POC Tuberculosis Test Provides Results Within 15 Minutes
- Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
- Blood-Based Molecular Signatures to Enable Rapid EPTB Diagnosis
- 15-Minute Blood Test Diagnoses Life-Threatening Infections in Children
- High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample
- Fast Noninvasive Bedside Test Uses Sugar Fingerprint to Detect Fungal Infections
- Rapid Sepsis Diagnostic Device to Enable Personalized Critical Care for ICU Patients
- Microfluidic Platform Assesses Neutrophil Function in Sepsis Patients
Channels
Molecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







